FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080285871> ?p ?o ?g. }

• W2080285871 endingPage "d1569" @default.
• W2080285871 startingPage "d1569" @default.
• W2080285871 abstract "<b>Objective</b> To investigate the impact of industry funding on reporting of subgroup analyses in randomised controlled trials. <b>Design</b> Systematic review. <b>Data sources</b> Medline. <b>Study selection</b> Randomised controlled trials published in 118 core clinical journals (defined by the National Library of Medicine) in 2007. 1140 study reports in a 1:1 ratio by high (five general medicine journals with largest number of total citations in 2007) versus lower impact journals, were randomly sampled. Two reviewers, independently and in duplicate, used standardised, piloted forms to screen study reports for eligibility and to extract data. They also used explicit criteria to determine whether a randomised controlled trial reported subgroup analyses. Logistic regression was used to examine the association of prespecified study characteristics with reporting versus not reporting of subgroup analyses. <b>Results</b> 469 randomised controlled trials were included, of which 207 (44%) reported subgroup analyses. High impact journals (adjusted odds ratio 2.64, 95% confidence interval 1.62 to 4.33), non-surgical (versus surgical) trials (2.10, 1.26 to 3.50), and larger sample size (3.38, 1.64 to 6.99) were associated with more frequent reporting of subgroup analyses. The strength of association between trial funding and reporting of subgroups differed in trials with and without statistically significant primary outcomes (interaction P=0.02). In trials without statistically significant results for the primary outcome, industry funded trials were more likely to report subgroup analyses (2.29, 1.30 to 4.72) than non-industry funded trials. This was not true for trials with a statistically significant primary outcome (0.79, 0.46 to 1.36). Industry funded trials were associated with less frequent prespecification of subgroup hypotheses (31.3% <i>v</i> 38.0%, adjusted odds ratio 0.49, 0.26 to 0.94), and less use of the interaction test for analyses of subgroup effects (41.4% <i>v</i> 49.1%, 0.52, 0.28 to 0.97) than non-industry funded trials. <b>Conclusion</b> Industry funded randomised controlled trials, in the absence of statistically significant primary outcomes, are more likely to report subgroup analyses than non-industry funded trials. Industry funded trials less frequently prespecify subgroup hypotheses and less frequently test for interaction than non-industry funded trials. Subgroup analyses from industry funded trials with negative results for the primary outcome should be viewed with caution." @default.
• W2080285871 created "2016-06-24" @default.
• W2080285871 creator A5000473326 @default.
• W2080285871 creator A5001826650 @default.
• W2080285871 creator A5001861927 @default.
• W2080285871 creator A5009362952 @default.
• W2080285871 creator A5009424802 @default.
• W2080285871 creator A5012215238 @default.
• W2080285871 creator A5013315390 @default.
• W2080285871 creator A5017390449 @default.
• W2080285871 creator A5017952355 @default.
• W2080285871 creator A5019888759 @default.
• W2080285871 creator A5031717153 @default.
• W2080285871 creator A5041615321 @default.
• W2080285871 creator A5042962646 @default.
• W2080285871 creator A5045556692 @default.
• W2080285871 creator A5046215571 @default.
• W2080285871 creator A5060053516 @default.
• W2080285871 creator A5060222179 @default.
• W2080285871 creator A5063394859 @default.
• W2080285871 creator A5069859261 @default.
• W2080285871 creator A5070476857 @default.
• W2080285871 creator A5071084763 @default.
• W2080285871 creator A5078747501 @default.
• W2080285871 creator A5085030861 @default.
• W2080285871 creator A5090318508 @default.
• W2080285871 date "2011-03-28" @default.
• W2080285871 modified "2023-10-17" @default.
• W2080285871 title "The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic review" @default.
• W2080285871 cites W1592228396 @default.
• W2080285871 cites W1605423339 @default.
• W2080285871 cites W1967849656 @default.
• W2080285871 cites W1971141955 @default.
• W2080285871 cites W1977833499 @default.
• W2080285871 cites W1980472079 @default.
• W2080285871 cites W2007410119 @default.
• W2080285871 cites W2022419394 @default.
• W2080285871 cites W2023482608 @default.
• W2080285871 cites W2036246082 @default.
• W2080285871 cites W2050850397 @default.
• W2080285871 cites W2056651344 @default.
• W2080285871 cites W2074736802 @default.
• W2080285871 cites W2078110114 @default.
• W2080285871 cites W2090899812 @default.
• W2080285871 cites W2098931866 @default.
• W2080285871 cites W2108233388 @default.
• W2080285871 cites W2115878443 @default.
• W2080285871 cites W2116153150 @default.
• W2080285871 cites W2118410003 @default.
• W2080285871 cites W2120104507 @default.
• W2080285871 cites W2126919203 @default.
• W2080285871 cites W2136284733 @default.
• W2080285871 cites W2139294235 @default.
• W2080285871 cites W2142947341 @default.
• W2080285871 cites W2148958485 @default.
• W2080285871 cites W2164145340 @default.
• W2080285871 cites W2337821671 @default.
• W2080285871 cites W2492141817 @default.
• W2080285871 cites W2080765157 @default.
• W2080285871 cites W2115881392 @default.
• W2080285871 doi "https://doi.org/10.1136/bmj.d1569" @default.
• W2080285871 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6173170" @default.
• W2080285871 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21444636" @default.
• W2080285871 hasPublicationYear "2011" @default.
• W2080285871 type Work @default.
• W2080285871 sameAs 2080285871 @default.
• W2080285871 citedByCount "80" @default.
• W2080285871 countsByYear W20802858712012 @default.
• W2080285871 countsByYear W20802858712013 @default.
• W2080285871 countsByYear W20802858712014 @default.
• W2080285871 countsByYear W20802858712015 @default.
• W2080285871 countsByYear W20802858712016 @default.
• W2080285871 countsByYear W20802858712017 @default.
• W2080285871 countsByYear W20802858712018 @default.
• W2080285871 countsByYear W20802858712019 @default.
• W2080285871 countsByYear W20802858712020 @default.
• W2080285871 countsByYear W20802858712021 @default.
• W2080285871 countsByYear W20802858712022 @default.
• W2080285871 countsByYear W20802858712023 @default.
• W2080285871 crossrefType "journal-article" @default.
• W2080285871 hasAuthorship W2080285871A5000473326 @default.
• W2080285871 hasAuthorship W2080285871A5001826650 @default.
• W2080285871 hasAuthorship W2080285871A5001861927 @default.
• W2080285871 hasAuthorship W2080285871A5009362952 @default.
• W2080285871 hasAuthorship W2080285871A5009424802 @default.
• W2080285871 hasAuthorship W2080285871A5012215238 @default.
• W2080285871 hasAuthorship W2080285871A5013315390 @default.
• W2080285871 hasAuthorship W2080285871A5017390449 @default.
• W2080285871 hasAuthorship W2080285871A5017952355 @default.
• W2080285871 hasAuthorship W2080285871A5019888759 @default.
• W2080285871 hasAuthorship W2080285871A5031717153 @default.
• W2080285871 hasAuthorship W2080285871A5041615321 @default.
• W2080285871 hasAuthorship W2080285871A5042962646 @default.
• W2080285871 hasAuthorship W2080285871A5045556692 @default.
• W2080285871 hasAuthorship W2080285871A5046215571 @default.
• W2080285871 hasAuthorship W2080285871A5060053516 @default.
• W2080285871 hasAuthorship W2080285871A5060222179 @default.
• W2080285871 hasAuthorship W2080285871A5063394859 @default.

• next